目的 分析新型冠狀病毒肺炎（COVID-19）住院患者阿茲夫定片的使用合理性及不良事件發(fā)生情況，為臨床合理用藥提供參考。方法 采用回顧性研究方法，對襄陽市中心醫(yī)院2022年11月1日—2022年12月31日因COVID-19住院且使用阿茲夫定片的患者進行全樣本點評，從藥物適應證、用法用量、給藥時機、用藥療程、聯(lián)合用藥等方面評價用藥合理性，同時考察用藥后不良事件發(fā)生率，評估用藥安全性。結果 使用阿茲夫定片的患者共計284例，其中122例用藥不合理，不合理率42.96%。不合理用藥共發(fā)生179例次，適應證不適宜74例次（26.06%），用法用量不適宜70例次（24.65%），聯(lián)合用藥不適宜24例次（8.45%）。使用阿茲夫定片患者中77例（27.11%）在用藥后共發(fā)生151項不良事件，其中血小板計數(shù)改變、乳酸升高、總膽汁酸升高及胃腸不適最常見。點評結果為“不合理”的病例不良事件發(fā)生率（35.25%）顯著高于點評結果為“合理”的病例（20.99%）。結論 阿茲夫定片臨床用藥存在不合理情況，且不合理用藥與患者住院期間不良事件的發(fā)生密切相關，臨床應用時應加強監(jiān)管和干預，促進臨床合理用藥，保障患者用藥安全。

Objective To analyze the clinical application rationality and adverse reactions of Azvudine Tablets in hospitalized patients with COVID-19 and to provide references for the rational drug use. Methods Data of the cases using Azvudine Tablets in Xiangyang Central Hospital from November 1, 2022 to December 31, 2022 were retrospectively collected and analyzed, in terms of indication, dosage and usage, medication timing, medication course, and combination of drugs. At the same time, the incidence of adverse reactions after drug use were investigated, in order to evaluate medication safety. Results There were a total of 284 cases using Azvudine Tablets among which 122 cases used unreasonably, with an unreasonable rate of 42.96%. There were totally 179 cases of unreasonable use of Azvudine Tablets including 74 cases (26.06%) of inappropriate indications, 70 cases (24.65%) of improper usage and dosage, and 24 cases (8.45%) of improper combination. A total of 151 adverse reactions occurred after Azvudine Tablets treatment for 77 patients (27.11%), of which platelet count change, lactic acid increase, total bile acid increase and gastrointestinal discomfort were the most common. And the incidence of adverse reactions (35.25%) of cases with "unreasonable" results was significantly higher than that with "reasonable" results (20.99%). Conclusion There were unreasonable use of Azvudine Tablets in clinic, which were closely related to the occurrence of adverse reactions, and need to be intervened in order to promote rational drug use and ensure drug safety of patients.

R978.7

湖北省衛(wèi)健委2018—2019年中醫(yī)藥科研項目（青年人才項目）（ZY2019Q013）；襄陽市2021年度醫(yī)療衛(wèi)生領域科技計劃項目（2021ZD05）